News & Events
22 Dec 2011 Invitation to apply to become an independent assessor of group 2 driving licence applicants
People with diabetes treated with insulin are now able to apply for any group two driving licence . The process of assessment will be
1) A driver wishing to apply for a Group 2 licence will first have to fill out a self-declaration form and consent.
2)Information will be obtained from their clinician (Consultant or GP). This will generate a fee that will be paid by the DVLA. Applicants who clearly fail on the criteria will not proceed further. Applicants whose application is rejected can reapply in the future if their circumstances change.
3) The DVLA will refer applicants who meet the criteria for an independent assessment by a consultant diabetologist, who will report to DVLA. A fee will be paid by the DVLA.
4) The final decision as to fitness to drive a class 2 vehicle will lie with the DVLA.
5) There is a right of appeal to a local magistrates or sheriffs court.
Although local diabetologists known to the patient may be involved at stage 2, the DVLA requires a rigorous independent assessment at stage 3. ABCD has agreed to assist the DVLA in identifying assessors for stage 3 (the independent assessment).Discussions are proceeding to set up a training programme for any consultant diabetologist holding a CST wishing to be an independent assessor. Meanwhile in view of the need to establish the assessment process without delay, consultants holding a CST in diabetes who feel that they have appropriate experience are invited to apply to the DVLA using the attached form.
Click here to download the application form.
Evidence from 85,760 patients with self-reported diabetes from the english general practice patient survey (Diabetes Care)
A new book review on Glycosmedia
Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study
The association between 25(OH)D concentration and type 2 diabetes is unlikely to be causal (The Lancet Diabetes & Endocrinology)
The effects of intravenous insulin infusions on early mortality for patients with acute coronary syndromes who present with hyperglycaemia: A matched propensity analysis using data from the MINAP database 2008–2012
As used in current clinical practice to treat hyperglycaemia in acute coronary syndromes, IVII appears to be of benefit only for patients with STEMI who are not known to have diabetes. IVII is associated with adverse early outcomes in patients with NSTEMI (European Heart Journal – Cardiovascular Care)
Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance
Liver fat was associated with iIGT but not with iIFG, whereas visceral adiposity was associated with both. Liver fat and visceral adiposity were associated with nT2D, whereas subcutaneous adiposity showed an inverse relationship with nT2D in women (International Journal of Medical Obesity)